The Indian Council of Medical Research (ICMR), has approved the Covid-19 Rapid Antigen Test kit (RAT), developed by  Meril, a global medical devices company, based out of India.

Meril is marketing the RAT under the brand name CoviFind and is capable of detecting the SARS-CoV-2 virus in infected individuals in 15 minutes, making it an effective tool in testing symptomatic individuals as well as those individuals who have come in close contact with infected patients.

CoviFind is one of the many medical breakthroughs achieved by the company since it was established in 2007, Meril manufactures advanced medical devices and diagnostics technologies in the range of vascular interventions, structural heart interventions, orthopaedic implants, ENT devices, endo-surgical devices, and a wide range of in-vitro diagnostics (IVD). Meril envisions augmenting the healthcare infrastructure and alleviating human suffering through its steadfast commitment to large-scale R&D and manufacturing of medical devices.
Meril has its headquarters in India, with an international business footprint in over 100 countries, and has 100% subsidiaries in India, the USA, Germany, Russia, Brazil, South Africa, Turkey and Bangladesh, along with operations in China & Australia. At present, Meril’s team comprises over 4,000 employees.